EBV structural antigens, gp350 and gp85, as targets for ex vivo virus- specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design

Journal of Immunology

Volumn 162, Issue 5, 1999, Pages 3063-3069

  Khanna, Rajiv ^a   Sherritt, Martina ^b   Burrows, Scott R ^b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; STRUCTURAL PROTEIN; VACCINE;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INFECTIOUS MONONUCLEOSIS; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TRANSGENIC MOUSE; VIRUS ADSORPTION; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

ACUTE DISEASE; ANIMALS; EPITOPES; FEMALE; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; INFECTIOUS MONONUCLEOSIS; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 0033104688     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Khanna, R., S. R. Burrows, and D. J. Moss. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387.
2. Morgan, A. J. 1992. Epstein-Barr virus vaccines. Vaccine 10:563.
3. Morgan, A. J., S. Finerty, K. Lovgren, F. T. Scullion, and B. Morein. 1988. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. J. Gen. Virol. 69:2093.
4. Morgan, A. J., M. Mackett, S. Finerty, J. R. Arrand, F. T. Scullion, and M. A. Epstein. 1988. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J. Med. Virol. 25:189.
5. Wilson, A. D., M. Shooshstari, S. Finerty, P. Watkins, and A. J. Morgan. 1996. Virus-specific cytotoxic T cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus (EBV). Clin. Exp. Immunol. 103:199.
6. Yao, Q. Y., M. Rowe, A. J. Morgan, C. K. Sam, U. Prasad, H. Dang, Y. Zeng, and A. B. Rickinson. 1991. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization. Int. J. Cancer 48:45.
7. Khanna, R., S. R. Burrows, J. Nicholls, and L. M. Poulsen. 1998. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur. J. Immunol. 28:451.
8. Moss, D. J., I. S. Misko, S. R. Burrows, K. Burman, R. McCarthy, and T. B. Sculley. 1988. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 331:719.
9. Salter, R. D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant T×B cell hybrid. EMBO J. 5:943.
10. Burrows, S. R., I. S. Misko, T. B. Sculley, C. Schmidt, and D. J. Moss. 1990. An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and b-type transformants. J. Virol. 64:3974.
11. Khanna, R. 1998. Tumour surveillance: missing peptides and MHC molecules. Immunol. Cell Biol. 76:20.
12. + virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. Virology 219:489.
13. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169.
14. Khanna, R., C. A. Jacob, S. R. Burrows, and D. J. Moss. 1993. Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. J. Immunol. Methods 164:41.
15. Khanna, R., C. A. Jacob, S. R. Burrows, M. G. Kurilla, E. Kieff, I. S. Misko, and D. J. Moss. 1991. Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T-cells. Immunology 74:504.
16. Vitiello, A., D. Marchesini, J. Furze, L. A. Sherman, and R. W. Chesnut. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1007.
17. Vitiello, A., A. Sette, L. Yuan, P. Farness, S. Southwood, J. Sidney, R. W. Chesnut, H. M. Grey, and B. Livingston. 1997. Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance. Eur. J. Immunol. 27:671.
18. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163.
19. Thorley-Lawson, D. A. 1980. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell. J. Immunol. 124:745.
20. Steven, N. M., N. E. Annels, A. Kumar, A. M. Leese, M. G. Kurilla, and A. B. Rickinson. 1997. Immediate early and early lytic cycle proteins arc frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185:1605.
21. + cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. USA 92:5845.
22. + cytotoxic T cell epitopes. J. Immunol. 157: 822.